Showing 91-100 of 9351 results for "".
- Cetaphil Brand Revamps RestoraDerm Product Linehttps://practicaldermatology.com/news/20141117-cetaphil_brand_revamps_restoraderm_product_line/2459061/Galderma Laboratories, LP unveiled a new and improved look for their Cetaphil RestoraDerm product line. The new look brings eczema to the forefront of the packaging featuring their new names, Cetaphil RestoraDerm Eczema Calming Body Wash and Cetaphil RestoraDerm Eczema Calming M
- Sente, Inc. Awarded European Patent for Active Ingredient in Proprietary Dermal Repair Creamhttps://practicaldermatology.com/news/20140619-sente_inc_awarded_european_patent_for_active_ingredient_in_proprietary_dermal_repair_cream/2459199/Sente has been granted the European Patent for use of a low molecular weight heparan sulfate (HS) for cosmetic products. HS is the most biologically active glycoprotein that is present in all layers of human skin and is the scientific base to Sente Inc's proprietary Dermal Repair Cream. M
- Residents Provided with Online Education by ASDShttps://practicaldermatology.com/news/20140416-residents_provided_with_online_education_by_asds/2459270/Kyle M. Coleman, MD, has developed a dermatologic surgery educational series as part of the ASDS Future Leaders Network. The "Better Surgical Education" video series, focusing on dermatologic surgery topics and procedures, will provide additional education opportunities for residency programs.
- SGR Patch: AADA Disappointed By Congressional Actionhttps://practicaldermatology.com/news/20140401-sgr_patch_aada_disappointed_by_congressional_action/2459285/Statement from Brett M. Coldiron, MD, FAAD President, American Academy of Dermatology Association: The U.S. House of Representatives and Senate have averted a 24 percent cut in Medicare physician payments by agreeing to a one-year short-term measure (HR 4302) to maintain current Medicare payment r
- Alphaeon Acquires US License To Teoxane Laboratories' Dermal Fillers And Cosmeceutical Productshttps://practicaldermatology.com/news/20130802-alphaeon_acquires_us_license_to_teoxane_laboratories_dermal_fillers_and_cosmeceutical_products/2459484/Alphaeon Corporation, a wholly-owned subsidiary of Strathspey Crown Holdings, LLC, has acquired an exclusive US license for the full line of products from Teoxane Laboratories. Containing 100 percent non-animal origin, resorbable hyaluronic acid, Teoxane's dermal fillers are currently available in m
- New Jersey Passes Law Prohibiting Indoor Tanning for Those Under 17https://practicaldermatology.com/news/20130402-new_jersey_passes_law_prohibiting_indoor_tanning_for_those_under_17/2459575/The state of New Jersey recently passed a law that bans minors under the age of 17 years old from using indoor tanning devices. The law passed both the New Jersey House and Senate in February and was signed into law by Gov. Christopher Christie on April 1, 2013. Dirk M. Elston, MD, FAAD, President o
- Sun Pharma, Mount Sinai Leaders Discuss Long-Term Vision Behind $2.5 Million Dermatology Endowmenthttps://practicaldermatology.com/news/sun-pharma-mount-sinai-leaders-discuss-long-term-vision-behind-25-million-dermatology-endowment/2488752/Sun Pharma’s’ $2.5 million endowed professorship at the Icahn School of Medicine at Mount Sinai represents an extension of a longstanding collaboration centered
- Phase 3 Trial of Oral Minoxidil Formulation Meets Primary Endpoints in Male Pattern Hair Losshttps://practicaldermatology.com/news/phase-3-trial-of-oral-minoxidil-formulation-meets-primary-endpoints-in-male-pattern-hair-loss/2488751/Veradermics announced positive topline results from its Phase 3 Study 304 evaluating VDPHL01, an investigational extended-release oral minoxidil formulation, in men with mild-to-moderate androgenetic alopecia. The randomized, double-blind, placebo-controlled trial met both co-primary endpoints at
- Oral Minoxidil Formulation VDPHL01 Meets Phase 3 Endpoints in Male Pattern Hair Losshttps://practicaldermatology.com/news/oral-minoxidil-formulation-vdphl01-meets-phase-3-endpoints-in-male-pattern-hair-loss/2488742/Veradermics announced positive topline results from a Phase 3 trial evaluating VDPHL01, its investigational extended-release oral minoxidil formulation, in men with androgenetic alopecia. The treatment met all primary and secondary endpoints, with statistically significant improvements in hair co
- "20 Tips in 20 Minutes" Offers Practical Pearls at Fall Clinicalhttps://practicaldermatology.com/news/20-tips-in-20-minutes-offers-practical-pearls-at-fall-clinical/2488740/Five dermatologists shared rapid-fire clinical, procedural, and practice-management advice, ranging from alopecia photography and nail examination to infantile hemangiomas, reimbursement, and patient communication at the 2026 Fall Clinical Dermatology Conference. The fast-moving "20 Tips i